Aequus Announces Delay in Filing Annual Financial Statements
02 mai 2022 20h30 HE
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, May 02, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) announces that the filing of its audited annual...
Aequus Announces Short Term Loan
02 mai 2022 08h00 HE
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, May 02, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) announces that it has entered into an agreement with...
Aequus Announces Director Resignation
22 avr. 2022 16h30 HE
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, April 22, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), a specialty pharmaceutical company with a focus on developing, advancing and...
Aequus Extends Commercial Agreement for Specialty Product Tacrolimus IR in Canada
24 janv. 2022 08h00 HE
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announced today that it has agreed to an extension...
Sandoz and Aequus Agree to 1-Year Extension on Vistitan in Canada
11 janv. 2022 09h00 HE
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on...
Aequus Announces Canadian Filing of NDS for Preservative-Free Glaucoma Medication
06 janv. 2022 09h00 HE
|
Aequus Pharmaceuticals
Health Canada Submission of Preservative-Free Prescription ‘Zimed PF’ Accepted for Screening VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS,...
Aequus Reports Third Quarter 2021 Financial Highlights
03 nov. 2021 05h00 HE
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on...
Aequus Reports Second Quarter 2021 Financial Highlights
30 août 2021 08h00 HE
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on...
Aequus Strengthens Clinical Experience in Stargardt Disease with Pediatric Ophthalmology Expertise
25 août 2021 08h00 HE
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”) a speciality pharmaceutical company, is pleased to announce that Dr....
Aequus and reVision to Collaborate on Stargardt Disease Program
17 août 2021 08h00 HE
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia and RIDGEWOOD, N.J., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”) and reVision Therapeutics, Inc. (“reVision”)...